kura
oncology
reports
preclinical
results
showing
antitumor
activity
tipifarnib
combination
inhibitor
head
neck
squamous
cell
carcinoma
preclinical
data
support
potential
expand
therapeutic
utility
tipifarnib
hras
dependent
tumors
representing
hnscc
company
plans
conduct
phase
study
tipifarnib
combination
inhibitor
relapsed
refractory
hnscc
san
diego
globe
newswire
kura
oncology
nasdaq
kura
biopharmaceutical
company
focused
development
precision
medicines
treatment
cancer
reported
new
preclinical
data
demonstrating
company
drug
candidate
tipifarnib
shows
compelling
activity
combined
inhibitor
models
hras
head
neck
squamous
cell
carcinoma
hnscc
including
tumors
mutations
amplifications
well
hras
overexpression
preclinical
data
presented
symposium
molecular
targets
cancer
therapeutics
saturday
copy
poster
available
kura
website
pipeline
publications
addition
conducting
ongoing
trial
tipifarnib
recurrent
metastatic
hras
mutant
hnscc
also
pioneering
new
approaches
expand
use
tipifarnib
larger
patient
populations
said
troy
wilson
president
chief
executive
officer
kura
oncology
compelling
preclinical
data
underscore
potential
combine
tipifarnib
inhibitor
treat
hnscc
patients
support
rationale
prioritize
phase
study
tipifarnib
combination
inhibitor
advanced
unresectable
relapsed
refractory
hnscc
harboring
mutations
amplifications
hras
hras
mutant
overexpressed
form
acts
key
node
center
hnscc
tumor
biology
represents
commonly
dysregulated
oncogene
hnscc
tumors
concluded
presentation
kura
preclinical
data
support
observation
hras
pathways
complementary
hnscc
providing
compensatory
mechanisms
resistance
single
agent
inhibition
specifically
additive
synergistic
activity
observed
administration
combination
tipifarnib
inhibitor
panel
xenograft
models
representative
hnscc
genotypes
estimated
hnscc
patients
tumors
overexpress
hras
additional
tumors
although
precise
overlap
hras
overexpressed
hnscc
populations
still
evaluated
company
believes
total
addressable
population
tipifarnib
may
high
hnscc
hnscc
head
neck
squamous
cell
carcinoma
hnscc
seventh
common
cancer
worldwide
accounting
new
cases
year
despite
advances
immunotherapy
prognosis
advanced
hnscc
patients
remains
poor
estimated
median
overall
survival
months
patients
stratified
expression
although
growth
factor
antibody
cetuximab
approved
decade
ago
development
therapies
hnscc
stymied
limited
number
druggable
targets
genomic
landscape
challenge
managing
drug
refractory
recurrent
metastatic
hnscc
tipifarnib
tipifarnib
potent
selective
orally
bioavailable
inhibitor
farnesyl
transferase
janssen
december
previously
tipifarnib
studied
cancer
patients
showed
compelling
durable
activity
certain
patient
subsets
however
molecular
mechanism
action
determined
could
explain
clinical
activity
across
range
solid
tumor
hematologic
indications
leveraging
advances
next
generation
sequencing
well
emerging
information
cancer
genetics
tumor
biology
company
seeking
identify
patients
likely
benefit
tipifarnib
tipifarnib
granted
fast
track
designation
food
drug
administration
treatment
patients
hras
mutant
hnscc
represents
hnscc
patients
kura
received
multiple
issued
patents
tipifarnib
providing
patent
exclusivity
foreign
countries
kura
oncology
kura
oncology
biopharmaceutical
company
committed
realizing
promise
precision
medicines
treatment
cancer
company
pipeline
consists
two
wholly
owned
small
molecule
drug
candidates
target
cancer
signaling
pathways
strong
scientific
clinical
rationale
improve
outcomes
identifying
patients
likely
benefit
treatment
kura
advanced
drug
candidate
tipifarnib
potent
selective
orally
bioavailable
farnesyl
transferase
inhibitor
currently
trial
patients
recurrent
metastatic
hras
mutant
hnscc
company
pipeline
also
highlighted
potent
selective
inhibitor
mll
interaction
currently
phase
clinical
trial
patients
relapsed
refractory
acute
myeloid
leukemia
aml
additional
information
kura
please
visit
company
website
statements
news
release
contains
certain
statements
involve
risks
uncertainties
could
cause
actual
results
materially
different
historical
results
future
results
expressed
implied
statements
statements
include
statements
regarding
among
things
kura
potential
growth
factors
may
cause
actual
results
differ
materially
include
risk
compounds
appeared
promising
early
research
clinical
trials
demonstrate
safety
efficacy
later
preclinical
studies
clinical
trials
risk
kura
oncology
may
obtain
approval
market
product
candidates
uncertainties
associated
performing
clinical
trials
regulatory
filings
applications
risks
associated
reliance
third
parties
successfully
conduct
clinical
trials
risks
associated
reliance
outside
financing
meet
capital
requirements
risks
associated
process
discovering
developing
commercializing
drugs
safe
effective
use
human
therapeutics
endeavor
building
business
around
drugs
urged
consider
statements
include
words
may
would
could
believes
estimates
projects
promise
potential
expects
plans
anticipated
intends
continues
designed
goal
negative
words
comparable
words
uncertain
list
description
risks
uncertainties
company
faces
please
refer
company
periodic
filings
securities
exchange
commission
available
statements
current
date
made
kura
oncology
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
contacts
company
pete
de
spain
vice
president
investor
relations
corporate
communications
pete
investors
robert
uhl
managing
director
westwicke
partners
llc
media
jason
spark
managing
director
canale
communications
jason
